|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
86,097,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$ - $ |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Annexon is a clinical-stage biopharmaceutical company developing a class of complement medicines designed to stop the classical complement pathway at its start, C1q, in order to bring therapies to patients suffering from serious complement-mediated autoimmune, neurodegenerative and ophthalmic disorders. Co. is developing a pipeline of product candidates designed to block the activity of C1q and the entire classical complement pathway for a range of complement-mediated diseases. Co.'s pipeline includes three clinical-stage assets across three therapeutic franchises: autoimmune, neurodegenration and ophtamology. Co. its developing its primary candidate, ANX005.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
3,200 |
353,200 |
653,200 |
5,754,246 |
Total Buy Value |
$19,411 |
$1,027,411 |
$1,667,131 |
$29,090,439 |
Total People Bought |
1 |
2 |
3 |
3 |
Total Buy Transactions |
1 |
2 |
3 |
5 |
Total Shares Sold |
17,898 |
59,898 |
62,990 |
73,114 |
Total Sell Value |
$98,919 |
$288,851 |
$300,713 |
$361,680 |
Total People Sold |
4 |
4 |
4 |
4 |
Total Sell Transactions |
7 |
9 |
12 |
17 |
End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Carson William H. |
|
|
2024-04-08 |
4 |
AB |
$6.07 |
$19,411 |
D/D |
3,200 |
3,200 |
|
- |
|
Yednock Ted |
EVP & CHIEF INNOVATION OFFICER |
|
2024-02-20 |
4 |
S |
$5.51 |
$14,348 |
D/D |
(2,604) |
72,471 |
|
- |
|
Overdorf Michael |
EVP & CHIEF BUSINESS OFFICER |
|
2024-02-20 |
4 |
S |
$5.48 |
$10,691 |
D/D |
(1,951) |
85,641 |
|
- |
|
Lew Jennifer |
EVP & CHIEF FINANCIAL OFFICER |
|
2024-02-20 |
4 |
S |
$5.53 |
$14,339 |
D/D |
(2,593) |
82,058 |
|
- |
|
Yednock Ted |
EVP & CHIEF INNOVATION OFFICER |
|
2024-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
39,000 |
75,075 |
|
- |
|
Overdorf Michael |
EVP & CHIEF BUSINESS OFFICER |
|
2024-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
39,000 |
87,592 |
|
- |
|
Lew Jennifer |
EVP & CHIEF FINANCIAL OFFICER |
|
2024-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
39,000 |
84,651 |
|
- |
|
Dananberg Jamie |
CHIEF MEDICAL OFFICER |
|
2024-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
39,000 |
39,000 |
|
- |
|
Artis Dean Richard |
EVP & CHIEF SCIENTIFIC OFFICER |
|
2024-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
39,000 |
89,329 |
|
- |
|
Overdorf Michael |
EVP & CHIEF BUSINESS OFFICER |
|
2024-02-12 |
4 |
S |
$5.53 |
$7,460 |
D/D |
(1,349) |
48,592 |
|
- |
|
Lew Jennifer |
EVP & CHIEF FINANCIAL OFFICER |
|
2024-02-12 |
4 |
S |
$5.54 |
$10,022 |
D/D |
(1,809) |
45,651 |
|
- |
|
Love Douglas |
PRESIDENT AND CEO |
|
2024-02-12 |
4 |
S |
$5.54 |
$32,032 |
D/D |
(5,782) |
196,121 |
|
- |
|
Yednock Ted |
EVP & CHIEF INNOVATION OFFICER |
|
2024-02-12 |
4 |
S |
$5.54 |
$10,027 |
D/D |
(1,810) |
36,075 |
|
- |
|
Yednock Ted |
EVP & Chief Innovation Officer |
|
2023-12-27 |
4/A |
AS |
$4.52 |
$94,966 |
D/D |
(21,000) |
37,885 |
|
- |
|
Yednock Ted |
EVP & Chief Innovation Officer |
|
2023-12-27 |
4/A |
OE |
$1.41 |
$34,176 |
D/D |
21,000 |
58,885 |
|
- |
|
Yednock Ted |
EVP & Chief Innovation Officer |
|
2023-12-27 |
4 |
AS |
$4.52 |
$94,966 |
D/D |
(21,000) |
0 |
|
- |
|
Yednock Ted |
EVP & Chief Innovation Officer |
|
2023-12-27 |
4 |
OE |
$1.41 |
$34,176 |
D/D |
21,000 |
21,000 |
|
- |
|
Satter Muneer A |
Director |
|
2023-12-26 |
4 |
B |
$2.88 |
$1,008,000 |
I/I |
350,000 |
7,406,024 |
2.25 |
- |
|
Lew Jennifer |
EVP & Chief Financial Officer |
|
2023-07-11 |
4 |
S |
$3.84 |
$4,055 |
D/D |
(1,057) |
47,460 |
|
- |
|
Yednock Ted |
EVP & Chief Innovation Officer |
|
2023-07-11 |
4/A |
AS |
$3.84 |
$4,055 |
D/D |
(1,057) |
37,885 |
|
- |
|
Overdorf Michael |
EVP & Chief Business Officer |
|
2023-07-11 |
4 |
S |
$3.84 |
$3,752 |
D/D |
(978) |
45,802 |
|
- |
|
Bcip Life Sciences Associates, Lp |
10% Owner |
|
2023-05-25 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
5,401,926 |
|
- |
|
Bcip Life Sciences Associates, Lp |
10% Owner |
|
2023-05-25 |
4 |
B |
$2.13 |
$639,720 |
I/I |
300,000 |
5,701,926 |
1.5 |
- |
|
Yednock Ted |
EVP & Chief Innovation Officer |
|
2023-03-16 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
21,000 |
|
- |
|
Yednock Ted |
EVP & Chief Innovation Officer |
|
2023-03-16 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
38,942 |
|
- |
|
83 Records found
|
|
Page 1 of 4 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|